Through the hint and knowledge that the intraperitoneal injection of luzindole can reduce calmodulin in platelets and in patients with AIS and that reducing melatonin can increase this (as proposed by Machida et al.), we believe that intraperitoneal injection of luzindole not only reduces melatonin in rats but also (1) promotes the secretion of melatonin in rats through the negative feedback regulatory mechanism and, (2) for the suppression of MT1B receptors, may increase the sensitivity of MT1A and MT2, further reducing calmodulin in platelets through some factors. Here, MT1A is linked to androgen insensitivity syndrome.